Tenascin-C levels in the vitreous of patients with proliferative vitreoretinopathy.
OBJECTIVE
To determine whether tenascin-C levels are elevated in the vitreous of patients with proliferative vitreoretinopathy (PVR).


METHODS
We assayed tenascin-C levels in vitreous samples of 110 consecutive patients with PVR (30 eyes), rhegmatogenous retinal detachment (RRD; 32 eyes), and macular hole or idiopathic epiretinal membrane (controls, 48 eyes) using an enzyme-linked immunosorbent assay.


RESULTS
Vitreous levels of tenascin-C (median [range]) were significantly greater in PVR (845.0 ng/ml [411.0-1,050.0]) than in RRD (21.9 ng/ml [13.2-127.0]) and in the controls (18.0 ng/ml [9.9-199.0]) (p < 0.0001).


CONCLUSIONS
The results indicate the possibility that tenascin-C is involved in the pathogenesis of PVR.
Mitamura
Yoshinori
Y
Department of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo, Japan. ymita@sapmed.ac.jp
Takeuchi
Shinobu
S
Ohtsuka
Kenji
K
Matsuda
Akira
A
Yamamoto
Teiko
T
Yamamoto
Shuichi
S
Hiraiwa
Noriko
N
Kusakabe
Moriaki
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012163:Retinal Detachment / Q000378:metabolism; D012167:Retinal Perforations / Q000378:metabolism; D019063:Tenascin / Q000378:metabolism*; D018630:Vitreoretinopathy, Proliferative / Q000378:metabolism*; D014822:Vitreous Body / Q000378:metabolism*
D019063:Tenascin